Cargando…

Digitalization in pharmaceutical industry: What to focus on under the digital implementation process?

Digitalization of any manufacture industry is a key step in any progress of the production process. The process of digitalization includes both increased use of robotics, automatization solutions and computerization, thereby allowing to reduce costs, to improve efficiency and productivity, and to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Hole, Glenn, Hole, Anastasia S., McFalone-Shaw, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528719/
https://www.ncbi.nlm.nih.gov/pubmed/34712948
http://dx.doi.org/10.1016/j.ijpx.2021.100095
_version_ 1784586308207771648
author Hole, Glenn
Hole, Anastasia S.
McFalone-Shaw, Ian
author_facet Hole, Glenn
Hole, Anastasia S.
McFalone-Shaw, Ian
author_sort Hole, Glenn
collection PubMed
description Digitalization of any manufacture industry is a key step in any progress of the production process. The process of digitalization includes both increased use of robotics, automatization solutions and computerization, thereby allowing to reduce costs, to improve efficiency and productivity, and to be flexible to changes. Pharmaceutical Industry (PI) has however been resistant to digitalization, mainly due to fair experience and complexity of the entailed development and manufacture processes. Nevertheless, there is a clear need to digitalize PI as the demand in both traditional and new drugs is constantly growing. Contract Development Manufacture Organizations (CDMOs) have a special digitalizing challenge. Digitalization of PI, and CDMO precisely, should be tightly related to the main aspects of Good Manufacture Practice (GMP), and, to succeed in PI digitalizing requires constant focus on GMP. Close collaboration with constantly changing stakeholders is another important factor which should be in focus during digitalization of CDMO. This paper represents an overview over the main aspects of CDMO digitalization and discusses both the opportunities and challenges of the process, focusing on the practical solutions for successive digital implementation.
format Online
Article
Text
id pubmed-8528719
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-85287192021-10-27 Digitalization in pharmaceutical industry: What to focus on under the digital implementation process? Hole, Glenn Hole, Anastasia S. McFalone-Shaw, Ian Int J Pharm X Mini Review Digitalization of any manufacture industry is a key step in any progress of the production process. The process of digitalization includes both increased use of robotics, automatization solutions and computerization, thereby allowing to reduce costs, to improve efficiency and productivity, and to be flexible to changes. Pharmaceutical Industry (PI) has however been resistant to digitalization, mainly due to fair experience and complexity of the entailed development and manufacture processes. Nevertheless, there is a clear need to digitalize PI as the demand in both traditional and new drugs is constantly growing. Contract Development Manufacture Organizations (CDMOs) have a special digitalizing challenge. Digitalization of PI, and CDMO precisely, should be tightly related to the main aspects of Good Manufacture Practice (GMP), and, to succeed in PI digitalizing requires constant focus on GMP. Close collaboration with constantly changing stakeholders is another important factor which should be in focus during digitalization of CDMO. This paper represents an overview over the main aspects of CDMO digitalization and discusses both the opportunities and challenges of the process, focusing on the practical solutions for successive digital implementation. Elsevier 2021-10-06 /pmc/articles/PMC8528719/ /pubmed/34712948 http://dx.doi.org/10.1016/j.ijpx.2021.100095 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Mini Review
Hole, Glenn
Hole, Anastasia S.
McFalone-Shaw, Ian
Digitalization in pharmaceutical industry: What to focus on under the digital implementation process?
title Digitalization in pharmaceutical industry: What to focus on under the digital implementation process?
title_full Digitalization in pharmaceutical industry: What to focus on under the digital implementation process?
title_fullStr Digitalization in pharmaceutical industry: What to focus on under the digital implementation process?
title_full_unstemmed Digitalization in pharmaceutical industry: What to focus on under the digital implementation process?
title_short Digitalization in pharmaceutical industry: What to focus on under the digital implementation process?
title_sort digitalization in pharmaceutical industry: what to focus on under the digital implementation process?
topic Mini Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528719/
https://www.ncbi.nlm.nih.gov/pubmed/34712948
http://dx.doi.org/10.1016/j.ijpx.2021.100095
work_keys_str_mv AT holeglenn digitalizationinpharmaceuticalindustrywhattofocusonunderthedigitalimplementationprocess
AT holeanastasias digitalizationinpharmaceuticalindustrywhattofocusonunderthedigitalimplementationprocess
AT mcfaloneshawian digitalizationinpharmaceuticalindustrywhattofocusonunderthedigitalimplementationprocess